

Attorney Docket No.: 6229.200-US

PATENT



#4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Christian Grøndahl, et al

Serial No.: 09/934,948

Group Art Unit: 1632

Filed: August 22, 2001

Examiner: To be assigned

Confirmation No.: 9075

For: Receptors and Signalling Proteins Capable of Binding Meiotic Acting Sterols (MAS)

**RESPONSE TO NOTICE TO FILE MISSING PARTS AND
TO COMPLY WITH SEQUENCE RULES**

Box Sequence
Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Notice to File Missing Parts dated October 9, 2001 (a copy thereof is attached hereto), Applicants submit the Combined Declaration and Power of Attorney signed and dated by Applicants for the above-captioned application.

Applicants also enclose certified copy of Danish application no.PA 2000 01259, filed 25 August 2000, priority of which is claimed under 35 U.S.C. 119.

Applicants also enclose herewith in response to the Notice to File Missing Parts dated October 9, 2001, the Sequence Listing for the above-captioned application and a 3.5" floppy disk containing the Sequence Listing. The content of the attached paper entitled "SEQUENCE LISTING" and of the accompanying identically labeled diskette is the same. Furthermore, the information contained in the attached "SEQUENCE LISTING" and the ASCII-encoded file is identical to the information in the specification as originally filed. No new matter is added.


I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR § 1.821(c) and (e), respectively, are the same.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this sequence listing.

Please charge the required fee, estimated to be \$130.00, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. Please credit any overpayment to Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Date: December 4, 2001

Respectfully submitted,



Cheryl H. Agris, Reg. No. 34,086
Outside Counsel for Novo Nordisk
of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



23650

PATENT TRADEMARK OFFICE



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/934,948	08/22/2001	Christian Grondahl	6229.200-US

23650
NOVO NORDISK OF NORTH AMERICA, INC
405 LEXINGTON AVENUE
SUITE 6400
NEW YORK, NY 10017

CONFIRMATION NO. 9075

FORMALITIES LETTER



OC000000006874663

Date Mailed: 10/09/2001

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).


- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(l) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- **The balance due by applicant is \$ 130.**
- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

20 141447 09934948
01/17/2002 VTRUONG1 0000020-141447 09934948
01 FC:105 130.00 CH
For Rules Interpretation, call (703) 308-4216

- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

A handwritten signature in black ink, appearing to read "Suzanne", is written over a horizontal line.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE